- Home
- FRGE vs CKPT Comparison
FRGE vs CKPT Comparison
Compare FRGE & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRGE
- CKPT
- Stock Information
- Founded
- FRGE 2014
- CKPT 2014
- Country
- FRGE United States
- CKPT United States
- Employees
- FRGE N/A
- CKPT N/A
- Industry
- FRGE Computer Software: Prepackaged Software
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- FRGE Technology
- CKPT Health Care
- Exchange
- FRGE Nasdaq
- CKPT Nasdaq
- Market Cap
- FRGE 176.0M
- CKPT 172.4M
- IPO Year
- FRGE N/A
- CKPT 2017
- Fundamental
- Price
- FRGE $0.57
- CKPT $4.04
- Analyst Decision
- FRGE Buy
- CKPT Buy
- Analyst Count
- FRGE 4
- CKPT 3
- Target Price
- FRGE $4.50
- CKPT $4.33
- AVG Volume (30 Days)
- FRGE 740.3K
- CKPT 5.7M
- Earning Date
- FRGE 03-05-2025
- CKPT 03-28-2025
- Dividend Yield
- FRGE N/A
- CKPT N/A
- EPS Growth
- FRGE N/A
- CKPT N/A
- EPS
- FRGE N/A
- CKPT N/A
- Revenue
- FRGE $79,329,000.00
- CKPT $41,000.00
- Revenue This Year
- FRGE $42.17
- CKPT $102,182.93
- Revenue Next Year
- FRGE $24.52
- CKPT $351.71
- P/E Ratio
- FRGE N/A
- CKPT N/A
- Revenue Growth
- FRGE 13.62
- CKPT N/A
- 52 Week Low
- FRGE $0.54
- CKPT $1.38
- 52 Week High
- FRGE $2.53
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- FRGE 39.81
- CKPT 65.90
- Support Level
- FRGE $0.54
- CKPT $4.01
- Resistance Level
- FRGE $0.73
- CKPT $4.07
- Average True Range (ATR)
- FRGE 0.07
- CKPT 0.03
- MACD
- FRGE 0.00
- CKPT -0.00
- Stochastic Oscillator
- FRGE 16.59
- CKPT 70.00
About FRGE Forge Global Holdings Inc.
Forge Global Holdings Inc is a financial service platform created to serve the needs of the private market. It provides marketplace infrastructure, data services, and technology solutions for private market participants. The Company offers a trusted trading platform, proprietary data and insights to inform investment strategies, along with custody services to help companies, shareholders, institutions and accredited investors confidently navigate and transact in the private market.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.